A Phase 2, Randomized, Multi-institutional Study of Nivolumab and Ipilimumab Versus Nivolumab, Ipilimumab and Stereotactic Body Radiation Therapy for Metastatic Merkel Cell Carcinoma
Latest Information Update: 29 Aug 2024
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Merkel cell carcinoma
- Focus Therapeutic Use
- 27 Aug 2024 Planned End Date changed from 1 Jul 2024 to 1 Sep 2024.
- 13 Jul 2023 Planned End Date changed from 1 Jul 2023 to 1 Jul 2024.
- 13 Sep 2022 Results presented at the 47th European Society for Medical Oncology Congress